CTOs on the Move


 
The Best Insulated Gallon Water Bottle. Portable, Convenient, 64 oz Water Jug With Straw And Carrying Sleeve. Glass, Stainless Steel, BPA Free. Easily Drink A Gallon A Day. Big Plastic And Metal Waterbottles.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Richman Root Delaney MD

Richman Root Delaney MD is a Waterford, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medi-EMR

Medi-EMR is a Bedminster, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Digital Healthcare

Digital Healthcare is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inter Parfums, Inc.

Inter Parfums, Inc. operates in the fragrance business, and manufactures, markets and distributes an array of fragrances and fragrance related products.

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.